Show simple item record

dc.contributor.authorLandskron, Johannesen_US
dc.contributor.authorKraggerud, Sigrid M.en_US
dc.contributor.authorWik, Elisabethen_US
dc.contributor.authorDørum, Anneen_US
dc.contributor.authorBjørnslett, Merete Paulineen_US
dc.contributor.authorMelum, Espenen_US
dc.contributor.authorHelland, Øysteinen_US
dc.contributor.authorBjørge, Lineen_US
dc.contributor.authorLothe, Ragnhild Aen_US
dc.contributor.authorSalvesen, Helgaen_US
dc.contributor.authorTasken, Kjetilen_US
dc.date.accessioned2018-04-26T12:57:36Z
dc.date.available2018-04-26T12:57:36Z
dc.date.issued2017-07-31
dc.PublishedLandskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett MP, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen H, Tasken K. C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLoS ONE. 2017;12(7):e0182030eng
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/1956/17661
dc.description.abstractThe pan lymphocyte marker CD45 exists in various isoforms arising from alternative splicing of the exons 4, 5 and 6. While naïve T cells express CD45RA translated from an mRNA containing exon 4, exons 4–6 are spliced out to encode the shorter CD45R0 in antigen-experienced effector/memory T cells. The SNP C77G (rs17612648) is located in exon 4 and blocks the exon’s differential splicing from the pre-mRNA, enforcing expression of CD45RA. Several studies have linked C77G to autoimmune diseases but lack of validation in other cohorts has left its role elusive. An incidental finding in an ovarian cancer patient cohort from West Norway (Bergen region, n = 312), suggested that the frequency of C77G was higher among ovarian cancer patients than in healthy Norwegians (n = 1,357) (3.0% vs. 1.8% allele frequency). However, this finding could not be validated in a larger patient cohort from South-East Norway (Oslo region, n = 1,198) with 1.2% allele frequency. Hence, C77G is not associated with ovarian cancer in the Norwegian population. However, its frequency was increased in patients with FIGO stage II, endometrioid histology or an age at diagnosis of 60 years or older indicating a possible association with a less aggressive cancer type.en_US
dc.language.isoengeng
dc.publisherPLOSeng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.titleC77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive diseaseen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2018-02-01T13:45:35Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2017 The Author(s)
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0182030
dc.identifier.cristin1497369
dc.source.journalPLoS ONE
dc.relation.projectNorges forskningsråd: 144182
dc.relation.projectNorges forskningsråd: 179571


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY